Industry

Industry — Pharmaceutical Contract Manufacturing for Sterile Injectables (India)

Onyx Biotec is not a drug company. It is a toll factory that fills sterile water and dry-powder antibiotics into ampoules and vials for brand-owners like Sun Pharma, Mankind and Aristo, under their labels. The arena has three tightly linked sub-industries: (i) sterile-water-for-injection (SWFI/WFI) — the diluent injected with most parenterals; (ii) dry-powder injectables, dominated by cephalosporin antibiotics; and (iii) the broader Indian pharmaceutical CDMO outsourcing pool. SWFI is a commodity volume business priced in paisa per ampoule; cephalosporin DPIs are a low-growth therapeutic with regulatory complexity; the CDMO wrapper gives a small Solan-based manufacturer access to top-20 Indian pharma demand. An SME pharma CDMO is a fixed-cost factory disguised as a manufacturer of branded products — capacity utilisation, not pricing, runs the P&L.

Takeaway: Onyx sits in Layer 2 — the conversion layer — selling capacity to Layer 3 brand-owners who keep the brand margin. The pricing power lives upstream of Onyx (in commoditised inputs) and downstream of Onyx (in branded retail), not in the layer Onyx occupies.

How This Industry Makes Money

A pharma CDMO charges its customer either a per-unit conversion fee (₹ per ampoule / vial filled, where the CDMO buys the raw materials) or a loan-licensing fee (a tolling charge where the customer ships in API and packaging). Onyx operates predominantly on the per-unit conversion model: it procures glass, granules and API, fills the product to client specifications, and bills against client purchase orders. The unit economics look more like a high-utilisation factory than a pharma brand.

Takeaway: The profit pool is bottom-heavy at the brand and API ends, and narrowest in the SME conversion segment where Onyx lives. The single biggest swing factor in this layer is capacity utilisation — the same ampoule line earns very different cents on the rupee at 50% vs 85% load. Sub-scale players that cannot hold ≥70% utilisation typically print mid-single-digit EBITDA margins; large CDMOs at 75-85% utilisation print 20%+.

Cost structure is heavily fixed once you take possession of a Form-Fill-Seal (FFS) line, a multi-column distillation plant and a cleanroom. Raw materials (LDPE granules, glass vials, butyl bungs, API powder, flip-off seals) are ~55-65% of cost of goods for a typical sterile CMO; conversion (labour, power, validation, depreciation, QC) is the remaining 35-45%. Working capital is heavy: top-10 customers can take 90-120 days to pay because brand-owners use CDMOs as a credit line. The "hidden line" in every CDMO P&L is the cost of regulatory compliance: WHO-GMP, USFDA inspections, EU-GMP audits, and now India's Revised Schedule M each carry six- to seven-figure capex tickets that are absorbed by the manufacturer, not the brand-owner.

Bargaining power asymmetry is severe. A top-10 customer that represents 10-20% of a CDMO's revenue can switch vendors with 60-90 days' notice. The reverse is not true — losing one customer in 100 dents your year. This is why client concentration is the single most-watched line in the segment.

Demand, Supply, and the Cycle

Underlying volume growth in Indian pharma is structural, not cyclical: 6-8% CAGR FY18-FY23, 9-11% expected for FY24 per ICRA, driven by lifestyle disease prevalence, expanding hospital infrastructure (~160,000 new beds per year per McKinsey), Jan Aushadhi expansion (10,607 outlets, target 25,000), and the Production Linked Incentive (PLI) scheme. The injectable sub-segment grows faster than oral — global dry powder injectables are projected to expand from $12.5B in 2023 to $22.8B by 2032 (~6.9% CAGR per dataintelo); the global Water-for-Injection market is projected from $30.5B in 2024 to $71.7B by 2035 (~8.0% CAGR per Transparency Market Research).

But the cycle in this layer is utilisation-driven, not price-driven.

Takeaway: For a sub-scale sterile CDMO, the cycle hits in this order: (1) end-customer demand softens → (2) brand-owner cuts purchase orders → (3) plant utilisation drops → (4) fixed-cost absorption collapses → (5) raw material cost-of-goods ratio rises → (6) receivable days stretch → (7) EBITDA margin halves before revenue moves much. The 2022 → 2023 SWI demand reversal at Onyx (revenue down 12%, EBITDA margin from 12.6% to 11.3%, capacity utilisation from 69.2% to 62.9%) is a textbook example: the trigger was the post-COVID end of vaccine-dilutant demand, not pricing.

Competitive Structure

The Indian pharmaceutical industry has 3,000 drug companies and ~10,500 manufacturing units across 60 therapeutic categories. The sterile-injectable contract-manufacturing pocket Onyx plays in is fragmented and price-competitive, not winner-take-most. The IPO prospectus describes the segment in management's own words as "highly competitive and fragmented." A handful of consolidated CDMOs at the top compete with hundreds of state-level WHO-GMP units at the bottom; in the middle sits a long tail of NSE SME-scale operators like Onyx.

Takeaway: The competitive set is not a clean ladder. The same brand-owners (Sun, Mankind, Aristo, Macleods) that are Onyx's top revenue customers also run their own internal injectable capacity and outsource only their peak load — making them both customer and latent competitor. The most economically dangerous competitor is not a peer like Akums but the next un-listed Solan SME offering the same SWFI ampoule at ₹0.10-0.20 less per unit. There is no defensible moat at the SWFI commodity end; the only moats are scale economics (Akums-level) or therapeutic complexity (Cohance-level), neither of which an SME-scale Solan site possesses.

Regulation, Technology, and Rules of the Game

Regulation, not technology, is the dominant external force. India's pharmaceutical regulatory framework changed materially in the past 24 months in ways that disproportionately affect SME sterile manufacturers.

Takeaway: Schedule M is the single regulation a reader of the rest of this report should keep in mind. Effective 31 December 2025 for sub-₹250 Cr manufacturers, it forces every Indian pharma SME — including every Solan competitor of Onyx — either to invest in PQS/QRM/cleanroom upgrades or to file a Form A and risk eventual closure. The longer-term effect is a structural contraction in the SME tail of Indian pharma manufacturing, which is supportive for compliant CDMOs that can absorb the displaced volume. The downside is that the same upgrade capex (HVAC, water systems, environment monitoring, electronic batch records) competes for cash that an SME like Onyx might otherwise spend on new product lines.

On the technology side, this is a mature small-molecule sterile space — Form-Fill-Seal ampoules, aseptic vial filling, multi-column distillation — not the biologics or cell-and-gene frontier. Innovation is incremental: high-speed cartoning, 21 CFR-compliant machines, large-volume parenteral capability, lyophilisation. None of these create a moat; they keep a player in the bid set.

The Metrics Professionals Watch

Takeaway: For a sterile CDMO, the three numbers that matter most in any given period are capacity utilisation, customer concentration, and debtor turnover. EBITDA margin is downstream of those three. ROCE is downstream of EBITDA margin and asset intensity. A reader who tracks only those three leading indicators will know about a turning point one to two quarters before it shows in earnings.

Where Onyx Biotec Limited Fits

Takeaway: Onyx is an SME-scale CDMO with table-stakes regulatory standing (WHO-GMP), heavy customer concentration (top-10 ≈ 94%), single-site geography risk, no regulated-market export optionality, and a recent (FY26) collapse into operating loss as Unit I utilisation slipped below 60%. The "industry backdrop" for Onyx is therefore mixed: the secular tailwind in Indian injectable contract manufacturing exists and is real, but Onyx's ability to capture it is constrained by scale, accreditation breadth, and customer-side bargaining power.

What to Watch First

The seven signals below are the fastest tells on whether the industry backdrop for Onyx is turning supportive or hostile. Each is observable in routine filings or accessible public data, so a reader can update the view between annual reports.